Organic Active Ingredients TRIZ Cases

Formula I substituted amides modulate the farnesoid X receptor, resolving stability versus toxicity trade-offs to improve therapeutic efficacy.

Linking Resiquimod to an anti-HER2 antibody overcomes tumor resistance by activating macrophages and dendritic cells to produce TNFα.

Adding polyethylene glycol to indomethacin formulations prevents low-temperature crystal precipitation while maintaining high percutaneous absorption.

Inhibiting specific transcription factors with nucleic acid agents restores damaged cardiac tissue by increasing cardiomyocyte division rates.

Nitrogen atmosphere processing prevents oxidation during polymer synthesis, eliminating leachable tin by-products in radiolabeled MIBG preparations.

Pyrimidinone compounds inhibit Lp-PLA2, reducing lysophosphatidylcholine production to treat atherosclerosis and Alzheimer's disease.

Amphiphilic polymer nanoaggregates solubilize poorly water soluble bioactive agents, eliminating complex surfactant systems and reducing manufacturing costs.

Targeting conserved 5'-UTR regions enables broad-spectrum efficacy against diverse rhinovirus strains, overcoming serotype variability.

Hsp70 stabilizes lysosomal membranes to enable broad-spectrum enzyme uptake, addressing high costs of specific replacements.

Segmented tetrahydropyran thiodisaccharides inhibit Galectin-3 to treat fibrotic diseases lacking effective inhibitors.

Combining anti-CD38 antibodies with survivin inhibitors targets hematological malignancies through enhanced cytotoxicity.

Flexible hydrogel matrix on expandable devices retains microparticulates during insertion, then releases them at the target site to prevent premature loss.

Multi-particle oral dosage form combines immediate and pH-sensitive delayed release particles to extend therapeutic phenylephrine levels beyond four hours.

Nootkatone treats depression with 95% clinical effectiveness, eliminating toxicity and side effects found in conventional antidepressants.

A nasal spray composition uses niacin-related compounds to induce vasodilation and reduce congestion.

Saracatinib targets Fyn kinase to interrupt Aβ-mediated neurotoxicity, addressing the failure of direct amyloid therapies to modify disease progression.

Deazapurine compounds inhibit Janus kinases by removing nitrogen from the purine ring to resolve limited inhibitor availability.

Specific primers and probes isolate EML4-ALK fusion sequences to resolve low detection precision, enabling targeted inhibitor screening for lung cancer therapy.

Modified SERM structures overcome tamoxifen resistance and reduce side effects by targeting PKCα-positive tumors without inducing uterine weight gain.

Substituted indole compounds inhibit Toll-like receptor 7, 8, and 9 signaling to reduce cytokine production in inflammatory diseases.

Nanoparticles carrying micheliolide derivatives sensitize cancer cells to ionizing radiation and immune checkpoint inhibitors.

Segmented Mpro inhibitors resolve the contradiction between treatment effectiveness and compound availability by optimizing residue positions.

siRNAs degrade DUX4 mRNA to lower toxic protein levels, addressing ineffective FSHD treatments.

Dynamic telmisartan dosing lowers urinary protein-to-creatinine ratio in dogs refractory to ACE inhibitors.

Segmenting the drug into a linear and circular strand protects the complex from nuclease degradation while reducing off-target effects.

Exosomes from cytotoxic T cells kill mesenchymal cells to suppress tumor proliferation and metastasis.

Specific microRNAs in blood samples diagnose osteoporosis, resolving low accuracy of bone density measurements in diabetic patients.

Selective CB2 receptor ligands modulate gene expression to restore vaginal tissue health without hormone replacement risks.

Inhibitors bind P-glycoprotein nucleotide domains to block efflux, restoring chemotherapy efficacy in resistant tumors.

Benzaldehyde mediated photo redox reaction creates selective beta-catenin BCL9 inhibitors.

A composition of ligustroflavone, rhoifolin, and hyperin inhibits influenza virus neuraminidase activity.

Optimized methyl salicylate content and 30000 to 75000 Pa modulus balance drug release with adhesion stability on moving joints.

A gelatinized HPMC hard capsule formulation controls 25-hydroxyvitamin D release using a cellulose ether and gellan gum matrix.

Specific Lactobacillus helveticus strains maintain immunomodulatory activity within complex nutritional matrices, reducing allergic symptoms.

Defined synthetic lipid species compositions enable standardized anti-phosphatidylethanolamine antibody detection in immunoassays.

A sustained-release tablet uses a composite gel matrix to trap active ingredients and deter injection misuse.

Palladium-catalyzed Suzuki coupling synthesizes the arylomycin ring, resolving low yield and racemization issues in antibiotic analog manufacturing.

Extracellular SLC26A3 inhibitors reduce oxalate absorption while minimizing systemic availability to treat constipation and kidney stones.

Segmented application protocols optimize biological interplay by sequencing cleansing actives before repair agents to maximize anti-aging benefits.

Non-aqueous vehicles prevent nucleophilic decomposition of mechlorethamine hydrochloride, reducing skin hypersensitivity while maintaining therapeutic potency.

Positive allosteric modulators bind distinct sites to boost endogenous ligand effects, avoiding rapid desensitization and sustaining therapeutic efficacy.

Overexpressing miR-200 family members reverses epithelial-to-mesenchymal transition, restoring sensitivity to cytotoxic therapies and reducing metastasis.

Modified nandrolone derivatives lacking C4-C5 double bonds enhance sexual desire through androgen receptor modulation.

A stable crystal form of a hepatitis B surface antigen inhibitor enhances drug bioavailability and stability.

Replacing citric acid with amino acids inhibits 7-epi-docetaxel formation, maintaining chemical stability for extended periods.

Imidazoquinoline derivatives activate toll-like receptors 7 and 8, resolving the lack of effective agonists for treating viral infections and cancers.

Analyzing miR-3151 and BAALC expression levels identifies acute myeloid leukemia patients with poor prognostic outcomes.